PADRINI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.136
AS - Asia 4.647
EU - Europa 2.913
AF - Africa 1.134
SA - Sud America 1.048
OC - Oceania 119
Continente sconosciuto - Info sul continente non disponibili 48
Totale 21.045
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.563
SG - Singapore 1.753
CN - Cina 832
BR - Brasile 662
HK - Hong Kong 542
VN - Vietnam 450
DE - Germania 332
FI - Finlandia 305
IT - Italia 283
GB - Regno Unito 251
UA - Ucraina 200
FR - Francia 194
SE - Svezia 176
PL - Polonia 158
RU - Federazione Russa 116
NL - Olanda 76
AR - Argentina 69
IN - India 64
TR - Turchia 57
ZA - Sudafrica 56
EC - Ecuador 48
ID - Indonesia 47
AO - Angola 43
GA - Gabon 43
JP - Giappone 41
MU - Mauritius 41
MX - Messico 41
PY - Paraguay 41
VE - Venezuela 41
PS - Palestinian Territory 40
UG - Uganda 40
KG - Kirghizistan 39
ME - Montenegro 38
RS - Serbia 38
SA - Arabia Saudita 38
SN - Senegal 38
BE - Belgio 37
CA - Canada 37
CO - Colombia 37
CV - Capo Verde 37
IQ - Iraq 37
ML - Mali 37
PE - Perù 37
AT - Austria 36
BB - Barbados 36
DK - Danimarca 36
IL - Israele 36
AL - Albania 35
BO - Bolivia 35
PA - Panama 35
UZ - Uzbekistan 35
CH - Svizzera 34
CZ - Repubblica Ceca 34
JO - Giordania 34
MY - Malesia 34
BJ - Benin 33
BZ - Belize 33
CI - Costa d'Avorio 33
IE - Irlanda 33
LU - Lussemburgo 33
MA - Marocco 33
MR - Mauritania 33
CW - ???statistics.table.value.countryCode.CW??? 32
ES - Italia 32
GH - Ghana 32
HN - Honduras 32
JM - Giamaica 32
LY - Libia 32
UY - Uruguay 32
AE - Emirati Arabi Uniti 31
AU - Australia 31
IR - Iran 31
KR - Corea 31
LC - Santa Lucia 31
MG - Madagascar 31
PK - Pakistan 31
AZ - Azerbaigian 30
BD - Bangladesh 30
KE - Kenya 30
CR - Costa Rica 29
GT - Guatemala 29
HR - Croazia 29
MD - Moldavia 29
TT - Trinidad e Tobago 29
AM - Armenia 28
BG - Bulgaria 28
HU - Ungheria 28
KZ - Kazakistan 28
MK - Macedonia 28
TN - Tunisia 28
CU - Cuba 27
EE - Estonia 27
GN - Guinea 27
LV - Lettonia 27
NP - Nepal 27
PR - Porto Rico 27
BF - Burkina Faso 26
CG - Congo 26
CM - Camerun 26
DO - Repubblica Dominicana 26
Totale 19.816
Salva come PNG Salva come JPEG
Città #
Fairfield 1.360
Singapore 968
Woodbridge 892
Ashburn 839
Chandler 770
Jacksonville 746
Houston 706
Ann Arbor 646
Wilmington 552
Hong Kong 518
Seattle 491
Cambridge 487
Princeton 303
Santa Clara 285
Boardman 253
Beijing 219
Dong Ket 163
San Diego 133
Nanjing 114
Bytom 113
Helsinki 107
Des Moines 103
Medford 103
Ho Chi Minh City 100
Roxbury 97
Los Angeles 83
Padova 83
Munich 77
Hanoi 60
New York 60
São Paulo 52
Chicago 44
Libreville 42
Kampala 39
Dakar 38
Bamako 37
Shenyang 36
Bridgetown 35
Luanda 34
Praia 34
Bishkek 33
Guangzhou 33
Panama City 33
Amman 32
Buffalo 32
Nanchang 32
Podgorica 32
Castries 31
Abidjan 30
Cotonou 30
Nouakchott 30
London 29
Tashkent 29
Norwalk 28
Warsaw 28
Baku 27
Lima 27
Montevideo 27
Willemstad 27
Antananarivo 26
Changsha 26
Conakry 26
Nairobi 26
Accra 25
Tokyo 25
Havana 24
Yerevan 24
Dushanbe 23
Jiaxing 23
Niamey 23
Vienna 23
Belo Horizonte 22
Dublin 22
Guatemala City 22
Johannesburg 22
Lusaka 22
Managua 22
Riga 22
Turku 22
Kingston 21
Noumea 21
Ouagadougou 21
Tirana 21
Ulan Bator 21
Harare 20
Hefei 20
Reykjavik 20
Tianjin 20
Vientiane 20
Addis Ababa 19
Andorra la Vella 19
Asunción 19
Gaborone 19
Maputo 19
Minsk 19
Nassau 19
Phnom Penh 19
San José 19
Stockholm 19
Tallinn 19
Totale 13.276
Salva come PNG Salva come JPEG
Nome #
Phthalates and heavy metals as endocrine disruptors in food: A study on pre-packed coffee products 412
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naive Patients with Non-Valvular Atrial Fibrillation 255
von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. 234
Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients with Alzheimer Disease 213
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register 213
Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors 211
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. 205
Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable? 204
Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms 198
R-warfarin anticoagulant effect 198
Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer’s disease 193
Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial 191
Perioperative Analgesic Efficacy and Plasma Concentrations of S(+)-Ketamine in Continuous Epidural Infusion During Thoracic Surgery. 186
Calcium-antagonist effects of norbormide on isolated perfused heart and cardiac myocytes of guinea-pig: a comparison with verapamil 184
Macrolides for KCNJ5–mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism 184
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study 181
A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy 180
Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. 179
VERAPAMIL AND NORVERAPAMIL PLASMA-LEVELS IN INFANTS AND CHILDREN DURING CHRONIC ORAL TREATMENT 177
Pharmacokinetics of Pentoxifylline and Its Main Metabolites in Patients With Different Degrees of Heart Failure Following a Single Dose of a Modified-Release Formulation 177
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. 176
Antihypertensive therapy in patients on chronic lithium treatment for bipolar disorders 175
Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis 173
A model-based support for diagnosing von Willebrand disease 173
A model-based approach to the automatic diagnosis of von Willebrand disease 170
Combinations of Polymorphisms in Genes Involved in the 5-Fluorouracil Metabolism Pathway Are Associated with Gastrointestinal Toxicity in Chemotherapy-Treated Colorectal Cancer Patients 169
Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. 167
Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes 166
Ranolazine-Induced Severe Bladder Hypotonia 165
A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease 164
AJMALINE TEST IN A PATIENT WITH CHRONIC-RENAL-FAILURE - A PHARMACOKINETIC AND PHARMACODYNAMIC STUDY 156
Adaptation of the QT interval to heart rate changes in isolated perfused guinea-pig heart: influence of amiodarone and d-sotalol. 156
Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties 155
Effect of CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function 153
Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment 153
Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world 153
Towards model-based diagnosis of von Willebrand disease 152
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours 150
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age 146
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old 145
Effects of phospholipase C on the electrical and mechanical activity of guinea pig taenia coli. 145
A model-based protocol for the diagnosis of von Willebrand disease 145
Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function 145
Antiarrhythmic drug plasma concentrations in ambulatory patients 142
Classification of thymidylate synthase gene enhancer region polymorphisms 142
Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium 139
DETERMINATION OF LORAJMINE AND ITS METABOLITE AJMALINE IN PLASMA AND URINE BY A NEW HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD 137
VKORC1, CYP2C9 AND CYP4F2 GENETIC BASED ALGORITHM FOR WARFARIN DOSING. PRELIMINARY RESULTS OF A PROSPECTIVE ITALIAN STUDY 137
Effect of dobutamine on left ventricular relaxation and filling phase in patients with ischemic heart disease and preserved systolic function 137
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. 136
UNDULY ENHANCED RESPONSE TO TOLVAPTAN IN A WOMAN SHOWING SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: AN INVESTIGATION OF POSSIBLE CAUSES 136
Identifying type Vicenza von Willebrand disease 135
Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer 134
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor 133
Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man 132
EFFECTS OF PINACIDIL ON GUINEA-PIG ISOLATED PERFUSED HEART WITH PARTICULAR REFERENCE TO THE PROARRHYTHMIC EFFECT 131
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. 130
A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele 129
Liver dysfunction markedly decreases the inhibition of CYP1A2-mediated theophylline metabolism by fluvoxamine 129
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy 128
Liver dysfunction markedly decreases the inhibition of cytochrome P450IA2-mediated theophylline metabolism by fluvoxamine 127
Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays 127
Evaluation of Serum/Urine Genomic and Metabolomic Profiles to Improve the Adherence to Sildenafil Therapy in Patients with Erectile Dysfunction 127
Neurohumoral effects of digitalis 126
Digitalis glycosides and plasma renin activity 126
Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure 126
Ibuprofen enantiomers in premature neonates with patent ductus arteriosus: Preliminary data on an unexpected pharmacokinetic profile of S(+)-ibuprofen 124
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms 123
Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. Ther Drug Monit. 2005 Dec;27(6):816-8. 122
EFFECTS OF PINACIDIL IN ISOLATED PERFUSED GUINEA-PIG HEART 121
Correlations between the enantio- and regio-selective metabolisms of warfarin 120
Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. 119
Once per week oral administration of amiodarone in the prophylaxis of supraventricular paroxysmal tachycardia 119
Renal excretion and diuretic effect of furosemide in patients with ascitic liver cirrhosis 118
Long-term persistence of antianginal effect of oral verapamil in chronic stable angina 118
Renal clearance of N(1)-methylnicotinamide: a sensitive marker of the severity of liver dysfunction in cirrhosis 117
Convective and adsorptive removal of β2-microglobulin during predilutional and postdilutional hemofiltration 117
Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers 116
Renal clearance of N-1-Methylnicotinamide is a marker of liver dysfunction in cirrhosis 113
Pharmacokinetics of lidocaine after bilateral ESP block 112
Apolipoprotein E (APOE) and warfarin dosing in an Italian population. 112
Effects of cardiopulmonary bypass on vancomycin plasma concentration decay. 109
[Anti-arrhythmia drugs of the '80s: something new with respect for the old]. 109
Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer 108
A report on the positive inotropic action of amrinone 108
Present and future trends in research and clinical applications of inodilators. 108
The calcium-channel blocker, Verapamil, does not improve portal pressure in patients with alco¬holic cirrhosis. 107
[New inotropic drugs]. 107
FARMACOLOGIA CLINICA DELL'IPERTENSIONE ARTERIOSA 106
Vasorelaxant effects of norbormide, a selective vasospastic agent for the rat microvasculature 106
Vasorelaxant effect of norbormide, a selective vasoconstrictor of rat microvasculature. 105
Amiodarone and amiodarone plus digitalis in the treatment of paroxismal supraventricular reciprocatine tachyarrhythmias 105
INHIBITORY EFFECT OF BERBERINE ON AGONIST-INDUCED CONTRACTION OF GUINEA-PIG AORTIC STRIPS 105
Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer 104
Twenty four-hour continuous indirect blood pressure monitoring during treatment with slow release metoprolol and atenolol 102
VKORC1, CYP2C9 and CYP4F2 pharmacogenetics: relevance in warfarin maintenance dose prediction among italian patients. 101
Pharmacodynamic variability of flecainide assessed by QRS changes 101
The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer 101
Intralesional topotecan in advanced ovarian cancer: A clinical report, based on a preclinical study 99
Calcium-agonist and antagonist effects of norbormide in isolated arteries and vascular smooth muscle cells. 97
Totale 14.632
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.398
article - articoli 54.837
book - libri 264
conference - conferenze 0
curatela - curatele 0
other - altro 194
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.578
Totale 121.271
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.365 0 0 0 0 0 175 51 170 287 200 223 259
2021/20221.959 61 301 184 157 79 120 71 208 91 39 213 435
2022/20231.677 381 155 26 181 287 237 10 109 211 9 63 8
2023/2024651 31 121 93 60 38 37 32 17 18 15 102 87
2024/20253.452 9 280 172 160 528 74 116 252 258 150 660 793
2025/20266.523 412 1.155 1.826 1.887 1.212 31 0 0 0 0 0 0
Totale 21.117